Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 03, 2026
Canaccord Genuity Maintains Buy Rating for Exact Sciences: Here's What You Need To Know
05:00pm, Wednesday, 22'nd Feb 2023 Benzinga
Canaccord Genuity has decided to maintain its Buy rating of Exact Sciences (NASDAQ:EXAS) and raise its price target from $70.00 to $75.00.
Shares of Exact Sciences are trading up 2.32% over the last 2
Exact Sciences (EXAS) Q4 Earnings Top Estimates, Margin Falls
01:33pm, Wednesday, 22'nd Feb 2023
Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences (EXAS) Q4 top line.
Exact Sciences (EXAS) Q4 2022 Earnings Call Transcript
03:30am, Wednesday, 22'nd Feb 2023 The Motley Fool
EXAS earnings call for the period ending December 31, 2022.
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
10:35pm, Tuesday, 21'st Feb 2023 Zacks Investment Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 20% and 6.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
After-Hours Action: What's Going On With Exact Sciences Stock?
10:17pm, Tuesday, 21'st Feb 2023 Benzinga
Exact Sciences Corp (NASDAQ: EXAS) shares are facing selling pressure after the close on Tuesday on the heels of the company's quarterly results.
What Happened: Exact Sciences said fourth-quarter
Exact Sciences Corporation (EXAS) Q4 2022 Earnings Call Transcript
09:07pm, Tuesday, 21'st Feb 2023
Exact Sciences Corporation (NASDAQ:EXAS ) Q4 2022 Earnings Conference Call February 21, 2023 5:00 PM ET Company Participants Megan Jones - Investor Relations Kevin Conroy - Chairman and Chief Executiv
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
06:49pm, Tuesday, 21'st Feb 2023
Exact Sciences (EXAS) delivered earnings and revenue surprises of 20% and 6.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
01:06pm, Monday, 20'th Feb 2023 Zacks Investment Research
High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) fourth-quarter top line.
5 Large-Cap Stocks Set to Beat on Q4 Earnings This Week
12:11pm, Monday, 20'th Feb 2023 Zacks Investment Research
The following five large-cap stocks are set to beat Q4 earnings estimates this week. These are: TECK, LECO, NI, EXAS and GFL.
5 Large-Cap Stocks Set to Beat on Q4 Earnings This Week
08:17am, Monday, 20'th Feb 2023
The following five large-cap stocks are set to beat Q4 earnings estimates this week. These are: TECK, LECO, NI, EXAS and GFL.
Cathie Wood Bulks Up On Shopify Amid Stock's 18% Post-Earnings Drop, Sells This Major Holding Up 30% This Week
02:35pm, Saturday, 18'th Feb 2023 Benzinga
Cathie Wood’s Ark Invest reversed its stance on Canadian e-commerce retailer Shopify, Inc. (NYSE: SHOP) and began bulking up on the stock this week.
Shopping For Shopify: Ark Invest, through its f
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
01:50pm, Friday, 17'th Feb 2023 Zacks Investment Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
10:32am, Friday, 17'th Feb 2023
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023?
04:00pm, Thursday, 16'th Feb 2023 The Motley Fool
Which of these rebounding biotech stocks is the better buy right now?
Why Earnings Season Could Be Great for Exact Sciences (EXAS)
01:36pm, Thursday, 16'th Feb 2023 Zacks Investment Research
Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
